Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques

Journal of Virology

Volumn 83, Issue 20, 2009, Pages 10384-10394

  Añez, Germán ^a   Men, Ruhe ^a   Eckels, Kenneth H ^b   Lai, Ching Juh ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; ENVELOPE PROTEIN; GLUTAMIC ACID; GLYCINE; HEPARAN SULFATE; HEPARIN; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CELL GROWTH; CERCOPITHECIDAE; COMPARATIVE STUDY; CONTROLLED STUDY; DENGUE VIRUS; DRUG SENSITIVITY; ENZYME INHIBITION; FETUS; GENE DELETION; IMMUNOGENICITY; KIDNEY CELL; LUNG ALVEOLUS CELL; MOLECULAR MODEL; MUTATION; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STRUCTURE; RHESUS MONKEY; SEQUENCE ANALYSIS; SUBSTITUTION REACTION; VERO CELL; VIREMIA; VIRUS DETECTION; VIRUS INFECTIVITY;

AEDES; ANIMALS; BASE SEQUENCE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; EPITHELIAL CELLS; FIBROBLASTS; GENETIC VARIATION; HEPARIN; KIDNEY; LUNG; MACACA MULATTA; MOLECULAR SEQUENCE DATA; MUTATION; SERIAL PASSAGE; VERO CELLS; VIRAL VACCINES;

CERCOPITHECUS AETHIOPS; DENGUE VIRUS TYPE 4; MACACA MULATTA;

EID: 70349756956     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01083-09     Document Type: Article

References (57)

1. Añez, G., R. Balza, N. Valero, and Y. Larreal. 2006. Economic impact of dengue and dengue hemorrhagic fever in the State of Zulia, Venezuela, 1997-2003. Rev. Panam Salud Publica 19:314-320. [In Spanish.]
2. Bernard, K. A., W. B. Klimstra, and R. E. Johnston. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103.
3. Burgoyne, G. H., K. D. Kajiya, D. W. Brown, and J. R. Mitchell. 1985. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine using FRhL-2 cells. J. Infect. Dis. 152:204-210.
4. Byrnes, A. P., and D. E. Griffin. 1998. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol. 72:7349-7356. (Pubitemid 28377866)
5. Byrnes, A. P., and D. E. Griffin. 2000. Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J. Virol. 74:644-651.
6. Chen, Y., T. Maguire, R. E. Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.
7. Durbin, A. P., R. A. Karron, W. Sun, D. W. Vaughn, M. J. Reynolds, J. R. Perreault, B. Thumar, R. Men, C. J. Lai, W. R. Elkins, R. M. Chanock, B. R. Murphy, and S. S. Whitehead. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65:405-413.
8. Eckels, K. H., D. R. Dubois, R. Putnak, D. W. Vaughn, B. L. Innis, E. A. Henchal, and C. H. Hoke, Jr. 2003. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am. J. Trop. Med. Hyg. 69:12-16.
9. Eckels, K. H., V. R. Harrison, P. L. Summers, and P. K. Russell. 1980. Dengue-2 vaccine: preparation from a small-plaque virus clone. Infect. Immun. 27:175-180.
10. Gandhi, N. S., and R. L. Mancera. 2008. The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des. 72:455-482.
11. Goncalvez, A. P., R. E. Engle, M. St Claire, R. H. Purcell, and C. J. Lai. 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. USA 104:9422-9427.
12. Gubler, D. J. 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10:100-103.
13. Halstead, S. B. 2007. Dengue. Lancet 370:1644-1652.
14. Halstead, S. B., N. J. Marchette, A. R. Diwan, N. E. Palumbo, R. Putvatana, and L. K. Larsen. 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. III. Reversion to virulence by passage of cloned virus in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 33:672-678.
15. Heil, M. L., A. Albee, J. H. Strauss, and R. J. Kuhn. 2001. An amino acid substitution in the coding region of the E2 glycoprotein adapts Ross River virus to utilize heparan sulfate as an attachment moiety. J. Virol. 75:6303-6309.
16. Heinz, F. X., and S. L. Allison. 2003. Flavivirus structure and membrane fusion. Adv. Virus Res. 59:63-97.
17. Hennessy, S., Z. Liu, T. F. Tsai, B. L. Strom, C. M. Wan, H. L. Liu, T. X. Wu, H. J. Yu, Q. M. Liu, N. Karabatsos, W. B. Bilker, and S. B. Halstead. 1996. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 347:1583-1586. (Pubitemid 26170875)
18. Jackson, T., F. M. Ellard, R. A. Ghazaleh, S. M. Brookes, W. E. Blakemore, A. H. Corteyn, D. I. Stuart, J. W. Newman, and A. M. King. 1996. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70:5282-5287. (Pubitemid 26240701)
19. Kapikian, A. Z., K. Midthun, Y. Hoshino, J. Flores, R. G. Wyatt, R. I. Glass, J. Askaa, O. Nakagomi, T. Nakagomi, R. M. Chanock, M. M. Levine, M. L. Clements, R. Dolin, P. F. Wright, R. B. Belshe, E. L. Anderson, and L. Potash. 1985. Rhesus rotavirus: a candidate vaccine for prevention of human rotavirus disease, p. 357-367. In R. A. Lerner, R. M. Chanock, and F. Brown (ed.), Vaccines 85. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
20. Kapoor, A., M. Jones, R. W. Shafer, S. Y. Rhee, P. Kazanjian, and E. L. Delwart. 2004. Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J. Virol. 78:7112-7123. (Pubitemid 38781549)
21. Kuhn, R. J., W. Zhang, M. G. Rossmann, S. V. Pletnev, J. Corver, E. Lenches, C. T. Jones, S. Mukhopadhyay, P. R. Chipman, E. G. Strauss, T. S. Baker, and J. H. Strauss. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
22. Lai, C. J., and T. P. Monath. 2003. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv. Virus Res. 61:469-509.
23. Lai, C. J., B. T. Zhao, H. Hori, and M. Bray. 1991. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc. Natl. Acad. Sci. USA 88:5139-5143.
24. Lee, E., R. A. Hall, and M. Lobigs. 2004. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J. Virol. 78:8271-8280. (Pubitemid 38944311)
25. Lee, E., and M. Lobigs. 2008. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J. Virol. 82:6024-6033. (Pubitemid 351822276)
26. Lee, E., and M. Lobigs. 2002. Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J. Virol. 76:4901-4911. (Pubitemid 34441696)
27. Lee, E., and M. Lobigs. 2000. Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. J. Virol. 74:8867-8875. (Pubitemid 30759585)
28. Lee, E., P. J. Wright, A. Davidson, and M. Lobigs. 2006. Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J. Gen. Virol. 87:2791-2801.
29. Lee, J. W., J. J. Chu, and M. L. Ng. 2006. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor αVβ3 integrin. J. Biol. Chem. 281:1352-1360.
30. Liu, C. C., S. C. Lee, M. Butler, and S. C. Wu. 2008. High genetic stability of dengue virus propagated in MRC-5 cells as compared to the virus propagated in Vero cells. PLoS ONE 3:e1810.
31. Malewicz, B., L. E. Anderson, K. Crilly, and H. M. Jenkin. 1985. Fetal rhesus monkey lung cells can be grown in serum-free medium for the replication of dengue-2 vaccine virus. In Vitro Cell Dev. Biol. 21:470-476. (Pubitemid 15245182)
32. Mandl, C. W., F. X. Heinz, E. Puchhammer-Stockl, and C. Kunz. 1991. Sequencing the termini of capped viral RNA by 5′-3′ ligation and PCR. BioTechniques 10:484-486.
33. Mandl, C. W., H. Kroschewski, S. L. Allison, R. Kofler, H. Holzmann, T. Meixner, and F. X. Heinz. 2001. Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo. J. Virol. 75:5627-5637.
34. Marchette, N. J., D. R. Dubois, L. K. Larsen, P. L. Summers, E. G. Kraiselburd, D. J. Gubler, and K. H. Eckels. 1990. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies. Am. J. Trop. Med. Hyg. 43:212-218.
35. Martinez-Barragan, J. J., and R. M. del Angel. 2001. Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection. J. Virol. 75:7818-7827.
36. Men, R., M. Bray, D. Clark, R. M. Chanock, and C. J. Lai. 1996. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70:3930-3937. (Pubitemid 26157374)
37. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 100:6986-6991.
38. Monath, T. P. 1994. Dengue: the risk to developed and developing countries. Proc. Natl. Acad. Sci. USA 91:2395-2400.
39. Monath, T. P. 2005. Yellow fever vaccine. Expert Rev. Vaccines 4:553-574.
40. Monath, T. P., J. Arroyo, I. Levenbook, Z. X. Zhang, J. Catalan, K. Draper, and F. Guirakhoo. 2002. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J. Virol. 76:1932-1943.
41. Moreno-Altamirano, M. M., F. J. Sanchez-Garcia, and M. L. Munoz. 2002. Non Fc receptor-mediated infection of human macrophages by dengue virus serotype 2. J. Gen. Virol. 83:1123-1130.
42. Munoz, M. L., A. Cisneros, J. Cruz, P. Das, R. Tovar, and A. Ortega. 1998. Putative dengue virus receptors from mosquito cells. FEMS Microbiol. Lett. 168:251-258.
43. Navarro-Sanchez, E., R. Altmeyer, A. Amara, O. Schwartz, F. Fieschi, J. L. Virelizier, F. Arenzana-Seisdedos, and P. Despres. 2003. Dendritic-cell- specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep. 4:723-728. (Pubitemid 36974759)
44. Nickells, J., M. Cannella, D. A. Droll, Y. Liang, W. S. Wold, and T. J. Chambers. 2008. Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. J. Virol. 82:12510-12519.
45. Okuno, Y., T. Fukunaga, M. Tadano, Y. Okamoto, T. Ohnishi, and M. Takagi. 1985. Rapid focus reduction neutralization test of Japanese encephalitis virus in microtiter system. Brief report. Arch. Virol. 86:129-135.
46. Prestwood, T. R., D. M. Prigozhin, K. L. Sharar, R. M. Zellweger, and S. Shresta. 2008. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J. Virol. 82:8411-8421.
47. Pugachev, K. V., F. Guirakhoo, S. W. Ocran, F. Mitchell, M. Parsons, C. Penal, S. Girakhoo, S. O. Pougatcheva, J. Arroyo, D. W. Trent, and T. P. Monath. 2004. High fidelity of yellow fever virus RNA polymerase. J. Virol. 78:1032-1038.
48. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:291-298.
49. Ryman, K. D., C. L. Gardner, C. W. Burke, K. C. Meier, J. M. Thompson, and W. B. Klimstra. 2007. Heparan sulfate binding can contribute to the neurovirulence of neuroadapted and nonneuroadapted Sindbis viruses. J. Virol. 81:3563-3573.
50. Sa-Carvalho, D., E. Rieder, B. Baxt, R. Rodarte, A. Tanuri, and P. W. Mason. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:5115-5123. (Pubitemid 27258183)
51. Sun, P., S. Fernandez, M. A. Marovich, D. R. Palmer, C. M. Celluzzi, K. Boonnak, Z. Liang, H. Subramanian, K. R. Porter, W. Sun, and T. H. Burgess. 2009. Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology 383:207-215.
52. Tassaneetrithep, B., T. H. Burgess, A. Granelli-Piperno, C. Trumpfheller, J. Finke, W. Sun, M. A. Eller, K. Pattanapanyasat, S. Sarasombath, D. L. Birx, R. M. Steinman, S. Schlesinger, and M. A. Marovich. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197:823-829.
53. van der Most, R. G., J. Corver, and J. H. Strauss. 1999. Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. Virology 265:83-95.
54. Volk, D. E., Y. C. Lee, X. Li, V. Thiviyanathan, G. D. Gromowski, L. Li, A. R. Lamb, D. W. Beasley, A. D. Barrett, and D. G. Gorenstein. 2007. Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364:147-154. (Pubitemid 46829273)
55. Wallace, R. E., P. J. Vasington, J. C. Petricciani, H. E. Hopps, D. E. Lorenz, and Z. Kadanka. 1973. Development of a diploid cell line from fetal rhesus monkey lung for virus vaccine production. In Vitro 8:323-332.
56. Yazi Mendoza, M., J. S. Salas-Benito, H. Lanz-Mendoza, S. Hernandez-Martinez, and R. M. del Angel. 2002. A putative receptor for dengue virus in mosquito tissues: localization of a 45-kDa glycoprotein. Am. J. Trop. Med. Hyg. 67:76-84.
57. Zhang, Y., W. Zhang, S. Ogata, D. Clements, J. H. Strauss, T. S. Baker, R. J. Kuhn, and M. G. Rossmann. 2004. Conformational changes of the flavivirus E glycoprotein. Structure 12:1607-1618.